Intervention Review

Monoamine oxidase B inhibitors for early Parkinson's disease

  1. Kristian Turnbull1,
  2. Robert Caslake1,
  3. Angus Macleod2,
  4. Natalie Ives3,
  5. Rebecca Stowe3,
  6. Carl Counsell1,*

Editorial Group: Cochrane Movement Disorders Group

Published Online: 20 JUL 2005

Assessed as up-to-date: 8 NOV 2011

DOI: 10.1002/14651858.CD004898.pub2


How to Cite

Turnbull K, Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD004898. DOI: 10.1002/14651858.CD004898.pub2.

Author Information

  1. 1

    University of Aberdeen, Division of Applied Health Sciences, Aberdeen, UK

  2. 2

    Southern General Hospital, Institute of Neurological Sciences, Glasgow, UK

  3. 3

    University of Birmingham, Birmingham Clinical Trials Unit, Birmingham, UK

*Carl Counsell, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. carl.counsell@abdn.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 20 JUL 2005

SEARCH

  1. Current Version

    Monoamine oxidase B inhibitors for early Parkinson's disease

    Kristian Turnbull, Robert Caslake, Angus Macleod, Natalie Ives, Rebecca Stowe and Carl Counsell

    Version of Record online: 20 JUL 2005 | DOI: 10.1002/14651858.CD004898.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Monoamine oxidase B inhibitors for early Parkinson's disease

    AD Macleod, CE Counsell, N Ives and R Stowe

    Version of Record online: 19 JUL 2004 | DOI: 10.1002/14651858.CD004898